Reliance earnings rebound as Jio listing lifts investor sentiment in India

Reliance earnings rebound as Jio listing lifts investor sentiment in India
Reliance rebounds on Jio boost

A strong stock market debut for Jio and a surge in quarterly profit are restoring momentum at Reliance as its legacy energy operations and newer consumer businesses both draw investor attention. The same week also brings a separate healthcare policy shift in India, with government-ordered price cuts set to lower the cost of hundreds of cancer drug brands from November 9.

Highlights

  • Jio raises $3.2bn in its IPO, stock surges 27 percent on debut, boosting market cap above $130bn and fueling Reliance's investor sentiment.
  • Reliance's September quarter consolidated net profit rises 33.8 percent year on year, with revenue up 27.8 percent to Rs3.62tn and oil-to-chemicals division driving record-high EBITDA of Rs625bn.
  • India's drug price regulator cuts prices for 543 cancer medicine brands effective November 9, aiming for Rs25bn in annual savings for patients after Supreme Court pressure.

Jio debut and refining strength drive rally

As reported by the Financial Times, Reliance is regaining investor confidence after Jio's market debut and a sharp rise in quarterly earnings highlighted the breadth of the group's business model.

Jio raises $3.2bn in its initial public offering, and the stock surges 27 per cent on its debut. That performance pushes its market capitalisation above $130bn, making it India's second-most valuable listed company after parent Reliance Industries.

Later in the week, the conglomerate reports one of its strongest quarterly performances yet. Consolidated net profit for the September quarter rises 33.8 per cent year on year, revenue jumps 27.8 per cent to a record Rs3.62tn, and earnings before interest, tax, depreciation and amortisation increase 23.9 per cent to an all-time high of Rs625bn.

The main support comes from the oil-to-chemicals division, where refining margins benefit from disruption in global energy markets linked to the conflict in the Middle East. Jio also posts a solid quarter by adding subscribers and improving average revenue per user.

Retail remains the weaker point, with growth of 6.4 per cent. Jeyandran Venugopal, head of Reliance Retail, tells analysts that margins should improve from next year as ecommerce investments scale up, while the company continues to spend on dark stores to catch up in India's quick-commerce market.

Market risks and lower drug prices reshape outlook

Reliance shares rise more than 11 per cent on Monday as brokerages reiterate buy ratings and investors respond to the upbeat results. Still, the durability of the earnings boost remains in focus because elevated refining margins are tied to exceptional geopolitical conditions that may ease if tensions in the Middle East subside.

The political backdrop in the U.S. is another variable for the group, with midterm election results due later today and likely to offer clues on future policy direction. The Trump administration has so far been seen as supportive of Reliance, a relationship underscored by Marco Rubio's visit to the Jamnagar refinery last month.

The week also brings a broader business and policy development in India, as prices of more than 100 cancer drugs are set to fall after government intervention on distributor mark-ups. India's drug price regulator revises the maximum retail prices of 543 medicine brands covering cancers including breast, prostate and colorectal cancer, with the new prices taking effect on November 9.

The move follows months of pressure from the Supreme Court, which calls the mark-ups "carnage" and reserves its verdict last week on a wider plea. The government's affidavit says distributor margins on some cancer drugs reach as high as 700 per cent, and the pharmaceuticals department says the changes will help patients save Rs25bn a year.

In our earlier article on how geopolitical tensions are increasing sovereign borrowing risks in a higher-rate environment, we explained that persistent shocks can lift inflation and funding costs while eroding governments’ fiscal headroom. We also noted that wars in Ukraine and the Middle East have pushed up energy and food prices, which tightens financial conditions and adds pressure across emerging markets.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.